OC
NDRM

Oppenheimer & Co’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Oppenheimer & Co’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,655
Closed -$337K – 1396
2017
Q3 		$337K Buy
8,655
+213
+3% +$7.83K 0.01% 994
2017
Q2 		$252K Buy
8,442
+30
+0.4% +$777 0.01% 1083
2017
Q1 		$223K Buy
+8,412
New +$208K 0.01% 1121
2015
Q3 		– Sell
-18,708
Closed -$287K – 1571
2015
Q2 		$287K Sell
18,708
-992
-5% -$14K 0.01% 1110
2015
Q1 		$265K Buy
19,700
+3,855
+24% +$47.4K 0.01% 1153
2014
Q4 		$222K Buy
+15,845
New +$125K 0.01% 1174

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Oppenheimer & Co's NDRM Position: Q4 2017 in Review

Oppenheimer & Co sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 8,655 shares — an estimated $337K sold.

Oppenheimer & Co first reported a position in NDRM in Q4 2014 and held it in 6 quarters. The position peaked at $337K in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Oppenheimer & Co reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Oppenheimer & Co sold 8,655 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $337K.
  • Oppenheimer & Co first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 6 quarters.
  • Oppenheimer & Co's NeuroDerm Ltd. Ordinary Shares position peaked at $337K in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Oppenheimer & Co's 13F filing for Q4 2017, filed 7 Feb 2018.